Skip to main content
EvidenceHealthcareVisualization detail

Venture capital raised by biopharma companies.

Biopharma-specific venture funding

Takeaway: The recovery is real but the capital is going to later-stage assets.

Biopharma VC

Venture capital raised by biopharma companies, $ billions.

Takeaway: The recovery is real but the capital is going to later-stage assets.

Biopharma VC

The recovery is real but the capital is going to later-stage assets.

Rendering the interactive chart…

Expand data table
Download CSV
Biopharma-specific venture funding: data table
PeriodSeriesValueValue basisSource
2023$bn raised23.3ActualBioPharma Dive: Biotech venture capital funding tracker
2024$bn raised26ActualBioPharma Dive: Biotech venture capital funding tracker

Biopharma-specific venture funding: full data table

SOURCEBioPharma Dive: Biotech venture capital funding tracker
VALUE BASISActual
LAST VERIFIEDSep 10, 2026
How this is calculated

Data table

Download CSV
Biopharma-specific venture funding: biopharma_vc data table (Biotech Venture Funding)
YearUSD bSeriesSourceValue basis
202323.3biopharma_vcBioPharma Dive: Biotech venture capital funding trackerActual
202426biopharma_vcBioPharma Dive: Biotech venture capital funding trackerActual

Method

How this evidence was built

What it measures

Two series with deliberately different scopes: "global biotech" is the broad sector total, "biopharma" is the narrower drug-developer subset. They are not alternative estimates of the same quantity and should not be compared point-to-point.

Key context

  • Venture funding totals vary materially between data providers depending on whether crossover rounds, corporate venture and non-dilutive grants are counted.
  • Each series here is kept to a single provider so the trend within a series is consistent.

Key numbers

  • Biotech VC peaked near $42bn in 2021 (mckinsey-biotech-vc).
  • Recovery to ~$38bn in 2025, a 28% gain on $29.7bn in 2024 (mckinsey-biotech-vc).
  • Biopharma raised $23.3bn (2023) and $26bn (2024) (biopharmadive-tracker).

Caveats

Caveat: 2020, 2022 and 2023 global totals are described qualitatively in the cited sources as a "funding winter" but no figure is published, so those years are omitted rather than estimated from the narrative.

Do not use this to

  • Stage or therapeutic-area breakdowns.
  • Deal counts or median round sizes.
  • Returns or exit outcomes.

Scope

2025

Sources

Last verified 10 Sept 2026

How relevant was this information?

Similar datasets